A Observational Study to Evaluate Effectiveness, Safety of Triple Combination Therapy of Zemidapa and Metformin in Patients With Type 2 DM Who Received Double or Triple Combination Therapy Including DPP4-inhibitor Other Than Gemigliptin
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The aim of this study is to evaluate the effectiveness and safety of the triple combination therapy of Zemidapa Tab. and Metformin in patients with type 2 diabete mellitus
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• type 2 DM Patients who are receiving one of the following three therapies during which the patients are prescribed with Zemidapa Tab. for the first time at the discretion of the attending physician:
‣ Double combination therapy (Metformin and a DPP-4 inhibitor other than Gemigliptin)
⁃ Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and a SGLT-2 inhibitor)
⁃ Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and Sulfonylurea \[SU\])
• patients with HbA1c results and who signed the written consent form
Locations
Other Locations
Republic of Korea
Chonnam National University Hwasun Hospital
RECRUITING
Hwasun
Contact Information
Primary
Study Lead
lgclinical@lgchem.com
82-2-6987-4156
Time Frame
Start Date: 2023-10-26
Estimated Completion Date: 2025-12-30
Participants
Target number of participants: 3000
Related Therapeutic Areas
Sponsors
Leads: LG Chem